Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Average cost to bring drug candidate to market = US$2.3 Bln

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 26, 2023 2:35pm

135 Views

Post# 35361353

RE:Average cost to bring drug candidate to market = US$2.3 Bln

And according to Deloitte's report this month, the average cost for Big Pharma to bring a drug to market for one indication was US$2.3 Billion in 2022 -

In ONCY's case this company has multiple cancer indications which represent multiples of value to the US$2.3 Billion average cost per indication.

Just sayin" .......

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing